alkannin has been researched along with Coronavirus Infections in 1 studies
Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Jin, Z | 1 |
Du, X | 1 |
Xu, Y | 1 |
Deng, Y | 1 |
Liu, M | 1 |
Zhao, Y | 1 |
Zhang, B | 1 |
Li, X | 1 |
Zhang, L | 1 |
Peng, C | 1 |
Duan, Y | 1 |
Yu, J | 1 |
Wang, L | 1 |
Yang, K | 1 |
Liu, F | 1 |
Jiang, R | 1 |
Yang, X | 2 |
You, T | 1 |
Liu, X | 2 |
Bai, F | 1 |
Liu, H | 1 |
Guddat, LW | 1 |
Xu, W | 1 |
Xiao, G | 1 |
Qin, C | 1 |
Shi, Z | 1 |
Jiang, H | 1 |
Rao, Z | 1 |
Yang, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Moderate COVID-19 Patients[NCT04484025] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-10-12 | Enrolling by invitation | ||
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients[NCT04483973] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-27 | Enrolling by invitation | ||
DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130] | Phase 2 | 11 participants (Actual) | Interventional | 2021-08-18 | Terminated (stopped due to Low COVID case numbers, competing COVID treatments available) | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31
Intervention | units on a scale (Median) |
---|---|
Cohort 1: Disulfiram | -2.60 |
Cohort 1: Placebo | -2.14 |
Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31
Intervention | copies/mL (Mean) |
---|---|
Cohort 1: Disulfiram 1000 mg | -20.89 |
Cohort 1: Placebo | -20 |
Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31
Intervention | fold change (Median) | |
---|---|---|
Change in IL-6 (pg/mL) Day 0 to 31 | Change in IL-1B (pg/mL) Day 0 to 31 | |
Cohort 1: Disulfiram 100 mg | -0.1186 | -0.1402 |
Cohort 1: Placebo | -0.0215 | 0.0268 |
The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31
Intervention | Participants (Count of Participants) | |
---|---|---|
AE Grade 3 or Higher | AE Grade 1 or 2 | |
Cohort 1: Disulfiram 1000 mg | 0 | 4 |
Cohort 1: Placebo | 1 | 1 |
1 other study available for alkannin and Coronavirus Infections
Article | Year |
---|---|
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |
Structure of M
Topics: Antiviral Agents; Betacoronavirus; Cells, Cultured; Coronavirus 3C Proteases; Coronavirus Infections | 2020 |